When Will The Johnson & Johnson Vaccine Be Authorized For Emergency Use? : Consider This from NPR A third COVID-19 vaccine could receive emergency use authorization from the Food and Drug Administration this month. The vaccine made by Johnson & Johnson is 66% effective in preventing moderate to severe disease, according to a global study.

Combined with the two vaccines currently in circulation, the U.S. could have three vaccines that are all highly effective at preventing death or hospitalization due to COVID-19.

Despite that promising news, NPR's Richard Harris reports on why the journey to herd immunity still won't be easy.

And Rae Ellen Bichelle goes inside a Colorado long-term care facility that has vaccinated nearly all of its residents. They say the initial steps to a return to normalcy feel great.

Additional reporting in this episode on the spread of coronavirus variants from NPR's Allison Aubrey.

In participating regions, you'll also hear a local news segment that will help you make sense of what's going on in your community.

Email us at considerthis@npr.org.
NPR logo

Third Vaccine On The Way, Fauci Hails 'Spectacular Results'

  • Download
  • <iframe src="https://www.npr.org/player/embed/962236361/963737803" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
Third Vaccine On The Way, Fauci Hails 'Spectacular Results'

Third Vaccine On The Way, Fauci Hails 'Spectacular Results'

Third Vaccine On The Way, Fauci Hails 'Spectacular Results'

  • Download
  • <iframe src="https://www.npr.org/player/embed/962236361/963737803" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

A third COVID-19 vaccine could receive emergency use authorization from the Food and Drug Administration this month. The vaccine made by Johnson & Johnson is 66% effective in preventing moderate to severe disease, according to a global study. Justin Tallis/AFP via Getty Images hide caption

toggle caption
Justin Tallis/AFP via Getty Images

A third COVID-19 vaccine could receive emergency use authorization from the Food and Drug Administration this month. The vaccine made by Johnson & Johnson is 66% effective in preventing moderate to severe disease, according to a global study.

Justin Tallis/AFP via Getty Images

A third COVID-19 vaccine could receive emergency use authorization from the Food and Drug Administration this month. The vaccine made by Johnson & Johnson is 66% effective in preventing moderate to severe disease, according to a global study.

Combined with the two vaccines currently in circulation, the U.S. could have three vaccines that are all highly effective at preventing death or hospitalization due to COVID-19.

Despite that promising news, NPR's Richard Harris reports on why the journey to herd immunity still won't be easy.

And Rae Ellen Bichelle goes inside a Colorado long-term care facility that has vaccinated nearly all of its residents. They say the initial steps to a return to normalcy feel great.

In participating regions, you'll also hear a local news segment that will help you make sense of what's going on in your community.

Email us at considerthis@npr.org.

This episode was produced by Brianna Scott, Lee Hale and Brent Baughman. It was edited by Sami Yenigun with help from Joe Neel, Scott Hensley, and Wynne Davis. Additional reporting from NPR's Allison Aubrey. Our executive producer is Cara Tallo.